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Abstract The aim of the study was to analyze the ability of the microorganism
Cunninghamella to carry out the biotransformation of 1-[3-(4-tert-butylphenoxy)-
propyl]piperidine (DL76) and to compare the obtained results with in silico models.
Biotransformation was carried out by three strains of filamentous fungus: Cunning-
hamella echinulata, Cunninghamella blakesleeana, and Cunninghamella elegans.
Most probable direction of DL76 metabolic transition was the oxidation of the
methyl group in the tert-butyl moiety leading to the formation of the metabolite
with I° alcohol properties. This kind of reaction was conducted by all three strains
tested. However, only in the case of C. blakesleeana that biotransformation product
had a structure of carboxylic acid. CYP2C19 was identified by Metasite software to
be the isoform of major importance in the oxidation process in the tert-butyl moiety
of DL76. In silico data coincide with the results of experiments conducted in vitro. It
was confirmed that Cunninghamella fungi are a very good model to study the
metabolism of xenobiotics. The computational methods and microbial models of
metabolism can be used as useful tools in early ADME-Tox assays in the process
of developing new drug candidates.
Keywords Cunninghamella . Biotransformation . Microbiological model . In vitro
metabolism . In silico metabolism
Introduction
Each drug before it is introduced to the market must undergo a complicated procedure. At the
beginning, it must be checked if a given structure is active; if yes, it is not the end of the
procedure. The metabolism of such a substance and its toxicity is also very important [1].
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Before the drug reaches to clinical trials and is administered to humans, there is another stage—
preclinical screening [2]. This stage gives us information about ADME(T)—absorption, distri-
bution, metabolism, excretion, and toxicology [3].
Drug metabolism studies can rely on the use of animal systems like mouse [4], rat
[5], or guinea pig [6] (in vivo). Unfortunately, these models suffer from a number of
limitations like ethical aspects, time that must be spend on breeding animals, and
last, but not least, cost of experimental models. Because of these disadvantages, use
of in vitro studies becomes an important tool for testing drugs and for production of
valuable drug metabolites. In vitro screening assays include human liver models, like
perfused liver [7], cell lines [8], hepatocytes [9], and liver slices [10]. S9 fractions
are very interesting because they contain both phase I and phase II activities and are
useful in the study of xenobiotic metabolism and drug interaction [11]. Human liver
microsomes are another popular in vitro model [12]. They are a rich source of drug-
metabolizing enzymes [13]. However, in vitro studies are not only on human liver
models. To elucidate the metabolism of xenobiotics, microbial cultures like bacteria
[14], fungi [15], or yeast [16] can be used. The cost of in vitro models is lower than
in vivo [17], culture and extraction of cytochrome P450 are simple [18], and in such
models, the so called “non-suffering organisms” are used.
Another way to study the metabolism of a drug is the so called in silico model. It
allows to predict the biological properties and parameters of ADME(T) by computa-
tional simulation [19]. However, neither in vitro models—cell or tissue culture,
microsomal preparations—nor in silico studies will replace animal system, but the
number of animals suffering from such tests may, or even must, be limited. One of
such widely used in vitro microbiological model is Cunninghamella [20].
Cunninghamella has specific properties which make this fungus very useful in studies of
drug metabolism. This property is the ability to metabolize a wide variety of drugs, over a
hundred of them, in manners that are similar to those in mammalian enzyme systems [20]. It
was proven that Cunninghamella has enzymes that are synonymous to those involved in
xenobiotic detoxification in mammals [21]. Moreover, there are many evidences [21, 22]
that Cunninghamella can predict the fate of the drug in the mammalian organism better than
other microorganisms.
The histamine H3 receptor (H3R) has been identified in the central nervous system
(CNS) and peripheral nervous system as a pre-synaptic receptor controlling the
release of histamine and numerous other neurotransmitters [23]. In the past, hista-
mine H3R antagonists were imidazole-containing compounds. Imperfection of these
structures appeared in unwanted hepatic cytochrome P450 inhibition and potential
drug–drug interactions. Therefore, a new class of non-imidazole histamine H3R
antagonists was designed and synthesized [24]. Potential therapeutic use of histamine
receptor ligands involves treatment of CNS diseases [25]. In our department for
many years, we were looking for new ligands of the H3R in a group of non-
imidazole derivatives. One of the newly synthesized compounds, 1-[3-(4-tert-butyl-
phenoxy)propyl]piperidine—DL76, was proved to be highly potent and orally avail-
able histamine H3 receptor antagonist (hH3R Ki022±3 nM—affinity for the
recombinant human H3R, stably expressed in CHO; ED50: 2.8±0.4 mg/kg) [26].
Referring to several studies confirming that microbial Cunninghamella model is able to
carry out metabolism in a manner similar to humans [20], we decided to check DL76
biotransformation pathway in in vitro model using different strains of Cunninghamella
(Fig. 1). The report also compares the results obtained from the microbial biotransformation
of the DL76 to the in silico model performed by a metabolism-simulating program Metasite.
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Materials and Methods
Substrates and Chemicals
The media required for the growth of Cunninghamella strains were purchased from BioShop
(Canada) (potato dextrose agar) and from Sigma-Aldrich (St Louis, MO, USA) (CSL, Corn
Steep Liquor). DL76 was synthesized in the Department of Chemical Technology and
Biotechnology of Drugs, Faculty of Pharmacy, Medical College of Jagiellonian University,
Cracow, Poland. HPLC-grade acetonitrile, dichloromethane, water, and formic acid were
obtained from Merck (Darmstadt, Germany). All other chemicals were of analytical reagent
grade and were obtained from Sigma-Aldrich.
Microorganisms and Culture Conditions
Cunninghamella echinulata NRRL 1384 (which was a gift from A.J. Carnell, University of
Liverpool, UK), Cunninghamella blakesleeana DSM 1906, and Cunninghamella elegans
DSM 1908 (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunsch-
weig, Deutschland) were propagated on potato dextrose agar (PDA) plate at 30 °C for
7 days. A fermentation basal medium (20-g D-glucose and 20-g corn step liquor in 1,000 ml
of water at pH5.0) was seeded with a 200-μl suspension of spore gained by wetting colonies
on solid medium PDA with sterile water.
Biotransformation Experiments
Biotransformation was carried out in a 50-ml fermentation medium, which was
inoculated with 200-μl suspension of corresponding Cunninghamella species. Micro-
organisms were cultured in 30 °C for 48 h. Flasks were shaken for the whole time.
After 2 days, 250 μl of the stock solution, which was prepared by dissolving 100 mg
of DL76 in 1 ml DMSO (the use of co-solvent was dictated by the poor solubility of
the substance in water; Log P05.09), was added to the fermentation medium. The
biotransformation was carried out for 7 days, and its progress was followed using thin
layer chromatography (TLC) and liquid chromatography electrospray ionization-



















Fig. 1 Possible direction of DL76 metabolism carried out by Cunninghamella
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Extraction of Products
During the subsequent days of biotransformation, 500-μl samples were taken from all
cultures. Each sample was extracted with methylene chloride. The water phase was sepa-
rated from organic phase. In the following experiment, only organic phase was used, which
next was dried over anhydrous sodium sulfate and concentrated in vacuo.
The cultures, after a 7-day biotransformation of DL76, were also extracted with methy-
lene chloride, and the whole organic phase after concentrated in vacuo was used to the
following studies.
Analytical Methods
For the identification of compound DL76 and its possible biotransformation products, both
TLC and LC-MS/MS were applied. TLC was performed using Merck aluminum plates
coated with silica gel with a thickness of 0.2 mm. It was concluded, as a result of many
experimental studies, that the most preferred developing system is a mixture of methylene
chloride and methanol (9:1+5 drops of NH3). Observation of the chromatograms was carried
out under UV light. The chromatograms were also stained with iodine.
Liquid Chromatographic Conditions
A liquid chromatography for determination of DL76 and its possible metabolites was
performed using an Agilent 1100 HPLC (Agilent Technologies, Waldbronn, Germany)
system consisting of a degasser, binary pump, a column oven, and an autosampler.
Chromatographic separation was carried on an XbridgeTM C18 analytical column (2.1×
30 mm, 3.5 μm;, Waters, Dublin, Ireland) with the oven temperature set at 30 °C. The
mobile phase of acetonitrile and water with an addition of 0.1 % formic acid with
gradient elution was set at flow rate of 0.3 ml. A sample volume of 10 μl was injected
into LC-MS/MS system.
As a detector, triple quadrupole mass analyzer API 2000 from Applied Biosystems Sciex
MDX (Concorde, Ontario, Canada) was used. Ionization was performed using the EPI (Elek-
trospray Ionization).
Mass Spectrometric Conditions
Mass spectrometric detection was performed on an Applied Biosystems MDS Sciex (Con-
cord, Ontario, Canada) API 2000 triple quadrupole mass analyzer equipped with an electro-
spray ionization (ESI) interface. ESI ionization was performed in the positive ion mode. The
ion source temperature was maintained at 450 °C. The ion spray voltage was set at 5,500 V.
The curtain gas (CUR) was set at 10 V and the collision gas (CAD) at 12 V. The optimal
collision energy was 50 V. Data acquisition and processing were accomplished using the
Applied Biosystems Analyst version 1.4.2 software.
Proton Nuclear Magnetic Resonance and IR spectra
Proton nuclear magnetic resonance (1H NMR) spectra were obtained in a Varian Mercury
spectrometer (Varian Inc., Palo Alto, CA, USA), in CDCl3, operating at 300 MHz. Chemical
shifts are reported in δ values (in parts per million) relative to TMS δ00 (1H), as internal
standard. The J values are expressed in Hertz (Hz). Signal multiplicities are represented by
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the following abbreviations: s (singlet), brs (broad singlet), d (doublet), t (triplet), and m
(multiplet). The IR spectra were recorded on a Jasco FT/IR 410 spectrometer (KBr pellets).
In Silico Studies
Computational simulation of metabolism of the title compound was carried out by use the
MetaSite software, demo version 2.1.0. (2005), Molecular Discovery Ltd.
MetaSite is a computational procedure to predict metabolism issues related to
cytochrome-mediated reactions in phase I metabolism. The methodology uses 3-D maps
of interaction energies between the protein, chemical probes, and the 3-D structure of the
compounds to be analyzed. MetaSite procedure is completely automated and does not
require any user assistance. All the work can be handled and submitted in batch queue.
The basic concept of MetaSite is to compare the interaction patterns inside the protein with
the 3-D structure of the ligand. The information obtained from a friendly user interface can
be easily translated into decisions in the drug discovery process.
Results and Discussion
In Vitro Biotransformation Study
In our study, three strains of filamentous fungus were used: C. echinulata NRRL 1348, C.
blakesleeana DSM 1906, and C. elegans DSM 1908.
During the study, the evidence that all strains are able to carry out the biotransformation
of DL76, novel histamine H3 receptor antagonist, were obtained. The samples from all
cultures were taken in the subsequent days of biotransformation, and TLC was performed.
The following Rf (retardation factor) values were obtained: 0.50–0.52 for DL76 and 0.34–
0.36 for its metabolites. It was noticed that in seventh day of biotransformation, no new
derivatives appeared. After completion of the reaction, samples were taken to investigate the
structure of the obtained derivatives of DL76. LC-MS/MS spectra were done. In the mass
spectrum of DL76, protonated molecule [M+H]+ at m/z 276 (Fig. 2a) was detected, which
corresponds to the molecular weight (275) of the parent molecule. In the mass spectra of
DL76 biotransformation products, protonated parent molecule ([M+H]+ at m/z 276), its
alcoholic and acidic metabolites (protonated ion [M+H]+ at m/z 292 and m/z 306, respec-
tively) were noticed (Fig. 2b–d).
We can assume, according to the LC-MS/MS spectra that the most probable direction of
metabolic transition of DL76 was the oxidation of the methyl group in the tert-butyl moiety
leading to the formation of a metabolite with alcohol I° properties (Fig. 2b–d). This kind of
reaction was biocatalised by all three strains (Fig. 1). However, only in the case of strain C.
blakesleeana that biotransformation product had the molecular ion corresponding to car-
boxylic acid (Figs. 1 and 2c).
C. echinulata NRRL 1384 was able to carry out the biotransformation in 100 %; there
was no trace of the presence of protonated ion at m/z 276 for DL76 (Fig. 2b). The level of
biotransformation carried out by C. elegans DSM 1908 was the lowest (Fig. 2d).
1H NMR and IR spectra for D76 and its metabolite after biotransformation using C.
echinulata NRRL 1384 were done. The 1H NMR spectra of DL76 represented one distinct
singlet which appeared at δ 1.34 for nine protons confirming the presence of three methyl
groups, the tert-butyl substituent. While in the 1H NMR spectra of DL76, metabolite singlet
at δ 1.39 was detected, suggesting only six protons for two methyl groups. Additionally,
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other singlet signals at δ 2.0 for one proton from hydroxyl group and at δ 3.78 for two
protons of methylene group (−CH2OH) were noticed. These last two singlets in the 1H NMR
spectra confirmed that biotransformation of D76 leads to oxidation of one of the three
methyl groups in the tert-butyl substituent. Also, the IR spectra of DL76 metabolite
confirmed the presence of hydroxyl functional group at 3,420 (OH). This group was not
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Fig. 2 a LC-MS/MS spectrum of DL76. The LC-MS/MS spectrum of metabolites of DL76 obtained after
biotransformation carried out by b C. echinulata NRRL 1384, c C. blakesleeana DSM 1906, and d C. elegans
DSM 1908
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DL76: 1-(3-(tert-butylphenoxy)propyl)piperidine
1H NMR (300 MHz, CDCl3): δ 1.34 (s, 9 H, 3 x CH3), 1.50 (s, 6 H, 3 x CH2 of piperidine),
1.81 (m, 2 H, CH2 ), 2.24 (t, 4 H, 2 x N-CH2 of piperidine, J06.54 Hz), 2.36 (m, 2 H, N-CH2),
3.39 (t, 2 H, O-CH2, J06.32Hz), 6.69 (d, 2 H, ArH, J07.50Hz), 7.18 (d, 2H, ArH, J07.74Hz).
IR (per centimeter): 2,953, 2,931, 2,867, 2,770, 1,610, 1,513, 1,466, and 1,230.
Metabolite of DL76: 2-methyl-2-(4-(3-(piperidin-1-yl)propoxy)phenyl)propan-1-ol)
1H NMR (300 MHz, CDCl3): δ 1 .39 (s, 6 H, 2 x CH3), 1.50 (s, 6 H, 3 x CH2 of
piperidine) 1.81 (m, 2 H, CH2 ), 2.0 (bs, 1 H, OH ), 2.23 (t, 4 H, 2 x N-CH2 of piperidine, J0
6.74 Hz), 2.36 (m, 2 H, N-CH2), 3.78 (s, 2 H, CH2OH), 3.94 (t, 2 H, O-CH2, J06.20 Hz),
6.65 (d, 2 H, ArH, J07.45 Hz), 7.20 (d, 2 H, ArH, J07.70 Hz). IR (per centimeter): 3,420,
3,005, 2,917, 1,646, 1,435, 1,406, and 1,224.
In Silico Biotransformation Study
Nowadays, different computational approaches are used to predict the position of metabo-
lism [27–30]. These approaches can be grouped into quantitative structure–activity
relationship-based, pharmacophore-based, structure-based (docking), reactivity-based, and
rule-based methods.
In our in silico study, MetaSite software was used to predict DL76 metabolic
transformation and particularly to help in the identification of the metabolite structure.
MetaSite is able to predict human CYP1A2, CYP2C9, CYP2C19, CYP2D6, and
CYP3A4 regioselective metabolism using only the 3-D structure of the given com-
pound. The recognition of the site of metabolism could be a significant step in
designing new compounds with a better pharmacokinetic profile. Labile compounds
can be stabilized when the site of metabolism is known by adding stable groups at
metabolically susceptible positions. MetaSite program does not give the structures of
metabolites that are formed but, by analyzing three-dimensional structure of mole-
cules, only suggests a probable site of attack of the enzyme. The site of metabolism is
described by a probability function (PSM) which is correlated to, and can be consid-
ered to be, an approximation of the free energy of overall process [27]. Figure 3 and
Table 1 show the MetaSite ranking of the probability of metabolism for the different
molecular positions. The MetaSite software applied to DL76 predicted sites of oxida-
tion by CYP2C19 in tert-butyl moiety: H-37, H-38, H-39, H-40, H-41, H-42, H-43,
H-44, and H-45 (PSM01.43) (Fig. 3). This result coincides with the data of conducted
experiment using Cunninghamella as a model to study the metabolism of xenobiotics.
MetaSite program moreover indicated the methylene group in alkyl chain which is
adjacent to the nitrogen atom of piperidine (H-31, H-32) as the very probable site of
oxidation process carried out by CYP1A2, CYP3A4, and CYP2D6 (Fig. 3). The
predicted value of PSM for CYP3A4 (1.7) and CYP1A2 (1.65) indicated that those
two isoforms might have the greatest importance in metabolic pathway of given
compound (Table 1), while CYP2C9 is the isoform which has the least importance
in the metabolism of methylene group (H-31, H-32) of DL76.
The oxidative and reductive capabilities of microorganisms, especially fungi, have
been well known for a long time and are used in preparative reactions. Among the
fungi, Cunninghamella species have the ability to metabolize a wide variety of xeno-
biotics in manners that are similar to those in mammalian enzyme systems [31–33]. The
genus Cunninghamella contains species of importance in medical mycology and in
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biotechnological processes. Cunninghamella bertholletiae, C. elegans, and C. echinulata
are the most common species.
Results of our research show similar direction of biotransformation reactions for
DL76 and terfenadine, described by Mazier et al. [34]. The tert-butyl moiety is the
same for both molecules, and the methyl group in the tert-butyl substituent is in both
compounds very sensitive to oxidation process. For the synthesis of active metabolite
fexofenadine, scientists used C. blakesleeana and another type of microbial organisms.
The transformation of terfenadine was carried out via oxidation of one of the methyl
groups in the tert-butyl substituent into alcohol and finally into carboxylic acid. The
process of obtaining fexofenadine from terfenadine by using microbial models was
patented [34]. The results of our studies confirm that Cunninghamella is a suitable
model to study the metabolism of compounds that have a chance to become a drug.
In conclusion, identification of the probable metabolites and the sites where molecular
metabolism could occur, using LC-MS/MS and MetaSite, can provide chemists with
knowledge that would help them in optimizing the structure of the compound in order to



































Fig. 3 Metabolic simulation of DL76 performed by MetaSite for isoforms of CYP450
Table 1 Value of the probability function (PSM) for selected DL76 atoms
CYP3A4 CYP1A2 CYP2D6 CYP2C9 CYP2C19
Atom PSM Atom PSM Atom PSM Atom PSM Atom PSM
H-37 H-37 H-37 H-37 H-37
H-38 0.5916 H-38 0.2694 H-38 0.6066 H-38 0.9166 H-38 1.4333
H-39 H-39 H-39 H-39 H-39
H-40 H-40 H-40 H-40 H-40
H-41 0.5916 H-41 0.2694 H-41 0.6066 H-41 0.9166 H-41 1.4333
H-42 H-42 H-42 H-42 H-42
H-43 H-4 3 H-43 H-43 H-43
H-44 0.5916 H-44 0.2694 H-44 0.6066 H-44 0.9166 H-44 1.4333
H-45 H-45 H-45 H-45 H-45
H-31 1.7000 H-31 1.6500 H-31 1.6000 H-31 1.2816 H-31 1.2225
H-32 H-32 H-32 H-32 H-32
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